Clinical Policy: Age Limit Override
Customize your policy alerts
Sign up for QualChoice Policy HIM.PA.177 alerts
Get alerted when Policy HIM.PA.177 changes without checking for updates manually.
Monitor payer policy activity
Governs medical necessity review and approval criteria when a member's age exceeds a health plan-approved formulary age limit for a drug that does not otherwise require prior authorization. Affects providers submitting requests for age limit overrides under the QualChoice (Centene-affiliated) health plans.
No material clinical or coverage changes in this revision.
Coverage Criteria for Age Limit Overrides
Initial Therapy
Covered when ALL of the following are met for initial approval:
All requests for non-formulary drugs should be reviewed against HIM.PA.103 Brand Name Override and Non-Formulary Medications.
Aspirin is approvable only for members 45 to 79 years of age.
Supported indication
- 4a: Prescribed indication is FDA-approved.
- 4b.i: NCCN Drug Information and Biologics Compendium level of evidence 1, 2A, or 2B.
See Appendix D.
- 4b.ii: Evidence from at least two high-quality, published studies or evidence-based clinical practice guidelines that: (1) adequately represent the member's clinical characteristics, age, and diagnosis; (2) adequately represent the prescribed drug regimen; (3) demonstrate clinically meaningful outcomes from the drug therapy; and (4) use appropriate experimental design and methods.
See Appendix F for additional information.
- 4b.iii: Micromedex DrugDex with strength of recommendation Class I or IIa.
See Appendix D.
- 4b.iv: For states with state-specific pediatric supportive evidence regulations, refer to Appendix G.
State addendums may apply.
Requests exceeding the health plan-approved quantity limit should also be reviewed against CP.PMN.59 Quantity Limit Override and Dose Optimization.
Continuation Therapy
Covered when ALL of the following are met for continued therapy:
Refer to state-specific addendums CC.PHARM.03A and CC.PHARM.03B.
Requests for benefit-excluded uses, including cosmetic indications, are not authorized under this policy. Such requests should be denied or redirected per plan rules and applicable exclusions. Benefit-excluded uses (e.g., cosmetic) are explicitly listed as non-authorizable reasons in the Initial Approval criteria.
Use is not medically necessary when the requirements in the Initial or Continued Therapy sections are not met. Examples of noncompliance that render a request not medically necessary include: the drug is aspirin outside the approvable age window (aspirin is approvable only for members 45 to 79 years of age), the member’s age does not exceed the health plan-approved age limit, the requested indication lacks required supportive evidence for off-label use, the requested dose exceeds the health plan-approved quantity limit, or the dose exceeds the FDA-approved maximum recommended dose for the relevant indication. Requests failing any of these criteria should be considered not medically necessary.
Initial Therapy — Age Limit Override
Initial Therapy
Covered when ALL of the following are met for initial approval (age limit override specific):
Approval duration: 12 months.
Continuation Therapy — Age Limit Override
Continuation Therapy
Covered when ALL of the following are met for continued therapy (age limit override specific):
See CC.PHARM.03A and CC.PHARM.03B for state specifics. Approval duration: 12 months.
Provider Actions and Documentation Requirements
Age Limit Override: prior authorization requirement
Age limit override applies when the request is for a formulary drug with a health plan-approved age limit that has been exceeded and the drug does not otherwise require prior authorization; the provider must submit clinical documentation and meet the policy criteria for approval.
- Applies only to formulary drugs (non‑formulary requests follow HIM.PA.103).
- Provider must submit supporting clinical documentation as described in policy.
Quantity limit interactions
If the requested dose exceeds the health plan‑approved quantity limit, the request must be reviewed in accordance with the Quantity Limit Override and Dose Optimization policy (CP.PMN.59).
- Requested dose must not exceed the health plan‑approved quantity limit.
- Requests exceeding quantity limits should be escalated to CP.PMN.59 for Quantity Limit Override and Dose Optimization review.
Required clinical documentation
Provider must submit documentation (such as office chart notes, laboratory results, or other clinical information) demonstrating that the member meets all approval criteria in this policy.
- Include clinical notes and objective data showing indication, prior response, and that age criteria and evidence requirements are met.
- Attach supporting studies or compendium references when the prescribed indication is off‑label and relies on cited evidence sources.
Triggers for denial
Requests may be denied when the approval criteria are not met, including specific triggers listed in the policy.
- Member’s age does not exceed the health plan‑approved age limit.
- Request is for aspirin outside the approvable age window (aspirin approvable only for members 45 to 79 years of age).
- Request is for a benefit‑excluded use (e.g., cosmetic).
- Requested dose exceeds the health plan‑approved quantity limit or exceeds the FDA‑approved maximum recommended dose for the relevant indication.
- Prescribed off‑label indication lacks the required supportive evidence sources (NCCN/DrugDex/peer‑reviewed studies/state pediatric requirements).
Quantity Limit Considerations
Definitions and Abbreviations
Background
This policy governs authorization when a member’s age is beyond a health plan–approved formulary age limit (AL). FDA-approved indications and labeled age ranges vary by product; approval for an age limit override requires that the prescribed indication be FDA-approved or, if off-label, supported by specified compendia or published evidence (for example, NCCN Drug Information levels 1/2A/2B, Micromedex DrugDex Class I/IIa, or at least two high-quality peer-reviewed studies meeting the policy’s criteria). The policy also excludes aspirin for most age overrides because aspirin is approvable only for members 45 to 79 years of age. Approval duration when criteria are met is 12 months.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.